Johan Karlsson Wallman
1 – 48 of 48
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
2024) In ACR Open Rheumatology(
- Contribution to journal › Article
-
Mark
Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor : results from 13 European registries
(
- Contribution to journal › Article
-
Mark
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis : Results From the European Spondyloarthritis Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
(
- Contribution to journal › Article
-
Mark
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis : a European routine-care observational study
(
- Contribution to journal › Article
-
Mark
Prescription of non-steroidal anti-inflammatory drugs for patients with inflammatory arthritis decreases with the initiation of tumour necrosis factor inhibitor therapy : results from the ICEBIO registry
2024) In Scandinavian Journal of Rheumatology(
- Contribution to journal › Article
-
Mark
Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis : what is the role of inflammation control?
(
- Contribution to journal › Article
- 2023
-
Mark
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017
(
- Contribution to journal › Article
-
Mark
Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register
(
- Contribution to journal › Article
-
Mark
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis : results from five Nordic biologics registries
(
- Contribution to journal › Article
-
Mark
Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis : an observational nationwide study
(
- Contribution to journal › Article
-
Mark
Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis : Results from the EuroSpA Research Collaboration Network
(
- Contribution to journal › Article
-
Mark
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
(
- Contribution to journal › Scientific review
-
Mark
How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis : Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses
(
- Contribution to journal › Article
-
Mark
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
(
- Contribution to journal › Article
-
Mark
Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors : Data from the EuroSpA collaboration
(
- Contribution to journal › Article
- 2021
-
Mark
Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis : results from the randomised controlled SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis
(
- Contribution to journal › Article
-
Mark
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis
(
- Contribution to journal › Article
-
Mark
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics : A Nordic population-based cohort study
(
- Contribution to journal › Article
-
Mark
Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine
(
- Contribution to journal › Article
-
Mark
Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis : Results From the SPARTAKUS Cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
- 2019
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
-
Mark
Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis : results from the SWEFOT trial population
(
- Contribution to journal › Article
-
Mark
Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis : Results from the SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis : pooled analysis of two phase 3 studies
(
- Contribution to journal › Article
- 2018
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
- 2017
-
Mark
A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure
(
- Contribution to journal › Article
-
Mark
Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy : A population-based regional cohort study from southern Sweden
(
- Contribution to journal › Article
- 2016
-
Mark
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
(
- Contribution to journal › Article
-
Mark
What PASSes for good? : Experience-based Swedish and hypothetical British EuroQol 5-Dimensions preference sets yield markedly different point estimates and patient acceptable symptom state cut-off values in chronic arthritis patients on TNF blockade
(
- Contribution to journal › Article
-
Mark
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis : Results of a Randomized Swedish Trial
(
- Contribution to journal › Article
-
Mark
Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis : Observational Data from Southern Sweden
(
- Contribution to journal › Article
- 2015
-
Mark
Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
(
- Contribution to journal › Article
-
Mark
Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients - baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
(
- Contribution to journal › Article
- 2014
-
Mark
Health economics and its measures in rheumatoid arthritis
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Is Swollen to Tender Joint Count Ratio a New and Useful Clinical Marker for Biologic Drug Response in Rheumatoid Arthritis? Results From a Swedish Cohort
(
- Contribution to journal › Article
- 2013
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
(
- Contribution to journal › Article
- 2011
-
Mark
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
(
- Contribution to journal › Article
- 2010
-
Mark
Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register
(
- Contribution to journal › Article
- 2008
-
Mark
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article